1 when 1 in 5 Americans will be over the age of 65. 2 AF not only causes debilitating symptoms and functional impairments owing to worsened hemodynamics and embolic stroke, it also increases the risk of mortality up to 1.5-to 1.9-fold. 3 Despite the significant morbidity and mortality burden incurred with AF, there are limited therapeutic options that may improve the outcomes of AF patients, and these options are associated with significant AF recurrence rates. 4 
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One possible explanation for the limitations of current therapies is that they do not address effectively or completely the underlying causes of AF. Evidence has been mounting that AF is associated with systemic and cardiac oxidation. 4, 5 Risk factors for AF are similar to those of atherosclerosis, a disease known to be perpetuated by oxidative stress. These risk factors, such as hypertension, aging, diabetes mellitus, and coronary artery bypass surgery, have each been associated with increases in the systemic markers of oxidation. 4 In addition, there is also evidence of increased cardiac oxidation of myofibrillar protein 5 and membrane lipids 6 with AF or with risk factors linked to AF. Although it is not clear whether cardiac oxidation leads to systemic markers of oxidation or whether systemic oxidation leads to cardiac oxidation, the association of oxidative stress and AF is robust and suggests that AF is possibly a manifestation of a systemic disease.
Despite the link between oxidative stress and AF, systemic antioxidant therapy for arrhythmias has not met with much success in clinical trials. 7, 8 This suggests that the oxidative stress is either not in the pathogenic cascade of arrhythmogenesis, or our current antioxidant therapies are not targeting the pathogenic source of oxidative stress in arrhythmia. Consistent with the later hypothesis, a recent article by Sovari et al 9 showed that angiotensin II (AngII)-induced ventricular arrhythmias could only be prevented by a mitochondria-targeted antioxidant rather than a general antioxidant or inhibitors of other producers of oxidative stress.
In this issue of Circulation, Purohit and colleagues 10 present an elegant study that they conducted with the use of human tissues and mouse models to demonstrate the crucial role of oxidized Ca 2+ and calmodulin-dependent protein kinase II (ox-CaMKII) in mediating AngII/pacing-induced AF. Purohit et al present strong, new evidence that oxidative stress can lead to AF. The proposed mechanistic link between the reninangiotensin system activation-induced oxidative stress, intracellular Ca 2+ handling, and the inducibility of AF also helps to explain the antiarrhythmic effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
AngII-Mediated CaMKII Oxidation Promotes Sarcoplasmic Reticulum Ca

2+
Leak, Potentiating Pacing-Induced AF Recent works by the Anderson group have identified that the oxidation of a pair of methionines (281/282) in the CaMKII regulatory domain prevents the inactivation of CaMKII 11 and that this constitutively active ox-CaMKII is responsible for AngII-induced sinoatrial node dysfunction 12 and aldosteronemediated cardiotoxicity. 13 In their article, Purohit et al 10 demonstrate that ox-CaMKII expression was increased in the atrial tissue from patients with AF in comparison with those in sinus rhythm, without affecting total CaMKII levels. Interestingly, the increase in atrial ox-CaMKII is not observed among AF patients treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. Using a mouse model of burst pacing-induced AF, they showed that 3 weeks of AngII infusion, a treatment known to increase atrial ox-CaMKII levels, 12 significantly increased the susceptibility to AF induction. By using the CaMKIIδ oxidation-resistant knock-in mice (MM-VV), they showed that this AngII-potentiated AF induction by burst pacing requires the presence of ox-CaMKIIδ, whereas the reactive oxygen species (ROS) production, hypertension, and cardiac hypertrophy in response to AngII treatment were unaffected in MM-VV mice. In addition, by using mouse models lacking functional NADPH oxidase (p47 −/− ) or cardiac-restricted expression of methionine sulfoxide reductase, they went on to show that NADPH oxidase-dependent ROS production and elevated ox-CaMKII are essential for the proarrhythmic effects of AngII in pacing-induced AF.
To determine whether increased sarcoplasmic reticulum (SR) Ca 2+ leak contributes to AngII-potentiated AF susceptibility, they measured the diastolic Ca 2+ sparks in isolated atrial myocytes, where the spontaneous Ca 2+ sparks and delayed afterdepolarizations (DADs) significantly increased in atrial myocytes from AngII-treated in comparison with saline-treated, wild-type mice. AngII-treated MM-VV mice
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Correspondence to Samuel C. 18 It would be of great interest to see if ox-CaMKII also plays a role in regulating these calcium regulatory proteins in AF patients and in the AngII/pacing-induced AF mouse model, as well.
Oxidative Stress and AF: A Complex Interplay
In the data presented by Purohit et al, inhibition of CaMKII oxidation by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers did not prevent all AF. This is consistent with the idea that there are more pathways and mechanisms involved than the one outlined by Purohit. The partial success of ablation therapy focused on creating lines of electrical conduction block in humans also suggests that CaMKII-enhanced triggered activity is not the whole mechanistic answer for AF, because this therapy likely affects reentry, and arrhythmogenic foci in places such as the pulmonary veins, as well. Other effects of AngII and oxidative stress include alterations in Na + current, and connexins can also contribute to forming the AF substrate. Changes in these proteins are mediated by protein kinase C (PKC) 19 and c-Src, 20 respectively. Mitochondrial dysfunction, associated with ROS release, enhances K ATP channel activity, further inhibiting conduction and creating the substrate for reentrant arrhythmias. 21 Mitochondria-targeting antioxidants and c-Src inhibitors, therefore, may prove to be clinically useful antiarrhythmic agents in the future. The data by Purohit et al point to the NADPH oxidase as a source of oxidative stress causing AF. Nevertheless, the results from Reilly et al 22 show that this enzyme is downregulated over time in AF, and the Statin Therapy for the Prevention of AF (SToP AF) trial 8 failed to show an effect of atorvastatin, a known inhibitor of the NADPH oxidase, to lower systemic oxidation or to prevent AF after cardioversion in patients with mostly persistent AF. One way to reconcile the observations of Purohit with the data above is that the NADPH oxidase may participate early in the initiation of AF, and some other process sustains the arrhythmia over time.
Although the Purohit idea provides a strong mechanistic link between ROS and AF, it does not explain the concept that AF begets AF, an idea that suggests a positive feedback loop in the maintenance of AF. In addition to structural changes with AF over time that also can be partially remediated by renin-angiotensin system inhibition, an interplay between PKC and mitochondrial ROS, where PKC activation induces mitochondrial ROS production 19 and mitochondrial ROS activates PKC, 23 is another candidate to explain the clinically demonstrated idea that AF perpetuates itself.
The work of Purohit adds an important piece to our understanding of AF, and each new piece suggests better therapies than we currently use. 
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